GS JT (Votrient pazopanib 200 mg)
Generic Name: pazopanib
Pill imprint GS JT has been identified as Votrient pazopanib 200 mg.
Votrient is used in the treatment of renal cell carcinoma; soft tissue sarcoma and belongs to the drug class VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Votrient pazopanib 200 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- pazopanib
- Imprint:
- GS JT
- Strength:
- pazopanib 200 mg
- Color:
- Gray
- Size:
- 14.00 mm
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- VEGF/VEGFR inhibitors
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- GlaxoSmithKline
- National Drug Code (NDC):
- 00173-0804
- Inactive Ingredients:
- magnesium stearate
microcrystalline cellulose
povidone
sodium starch glycolate type A potato
hypromelloses
ferrosoferric oxide
polyethylene glycol 400
polysorbate 80
titanium dioxide
| NDC Code | Manufacturer / Repackager |
|---|---|
| 00078-0670 | Novartis Pharmaceuticals Corporation |
Note: Inactive ingredients may vary.
More about Votrient (pazopanib)
Consumer resources
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
